Drugmakers Reassess Europe As Trump Overhauls Drug-Pricing Rules

RunWithRugs

2026-03-21 11:09:57

Abstract generation in progress

(MENAFN- Swissinfo) The US president’s Most Favoured Nation drug-pricing policy has triggered an earthquake across Europe as pharmaceutical giants scramble to protect their bottom lines. This content was published on March 20, 2026 - 09:00 10 minutes Jessica Davis Plüss (text) Pauline Turuban (visuals)

As the first anniversary of Donald Trump’s Most Favoured Nation (MFN) drug-pricing executive orderExternal link approaches, the policy, which is aimed at cutting US healthcare costs, is no longer just a protectionist threat on paper. The order, which effectively forces pharmaceutical companies to charge US consumers the same as in other wealthy countries, has started to gain teeth.

More More Healthcare innovation Swiss pharma’s global success meets worries at home

This content was published on Feb 13, 2026 Switzerland’s two biggest pharmaceutical companies are doing well. Why is the country so worried?

Read more: Swiss pharma’s global success meets worries at

MENAFN20032026000210011054ID1110888657

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes